Tempus AI
We're Hiring!
Tempus AI Innovation & Technology Culture
What People Are Saying About Tempus AI
-
Product Innovation: FDA PMA approval for the 648‑gene xT CDx companion diagnostic places Tempus’s genomic assay directly into regulated clinical decision pathways rather than research only. Real‑world, AI‑enabled tools (e.g., ECG‑AF, algorithmic scores layered on assays) underscore translation of AI from concepts to cleared, clinical products.
-
Process Innovation: The TIME Trial network, with Link/Next software, algorithmically screens and routes patients to studies and has reported faster activations and higher enrollments versus non‑TIME studies. This shows AI moving from insights to measurable operational impact in trial execution.
-
Differentiated Market Position: A multimodal data+software platform layered atop regulated assays and provider‑embedded apps positions Tempus beyond standalone testing or analytics vendors. Pharma collaborations and the SoftBank JV signal that large partners view this dataset and tooling as strategically distinct.































